The MAPK pathway mediates TLR signaling during innate immune responses. We discovered previously that MKP-1 is acetylated, enhancing its interaction with its MAPK substrates and deactivating TLR signaling. As HDACs modulate inflammation by deacetylating histone and nonhistone proteins, we hypothesized that HDACs may regulate LPS-induced inflammation by deacetylating MKP-1. We found that mouse macrophages expressed a subset of HDAC isoforms (HDAC1, HDAC2, and HDAC3), which all interacted with MKP-1. Genetic silencing or pharmacologic inhibition of HDAC1, -2, and -3 increased MKP-1 acetylation in cells. Furthermore, knockdown or pharmacologic inhibition of HDAC1, -2, and -3 decreased LPS-induced phosphorylation of the MAPK member p38. Also, pharmacologic inhibition of HDAC did not decrease MAPK signaling in MKP-1 null cells. Finally, inhibition of HDAC1, -2, and -3 decreased LPS-induced expression of TNF-␣, IL-1␤, iNOS (NOS2), and nitrite synthesis. Taken together, our results show that HDAC1, -2, and -3 deacetylate MKP-1 and that this post-translational modification increases MAPK signaling and innate immune signaling. Thus, HDAC1, -2, and -3 isoforms are potential therapeutic targets in inflammatory diseases. J. Leukoc. Biol. 95: 651-659; 2014.
Introduction
Microbial antigens stimulate TLRs, increasing the secretion of proinflammatory cytokines, such as TNF-␣ IL-1␤, IL-6, and NO, from innate immune cells [1] [2] [3] . TLR signaling is transduced through two major intracellular signaling pathways:
NF-B and MAPK pathways [4 -6] . For example, LPS activation of TLR4 signaling leads to phosphorylation of p38, ERK, and JNK MAPKs. Phosphorylated MAPKs enter into the nucleus and activate transcription factors, such as E 26-like transcription factor 1, myocyte enhancer factor-2, and c-Jun, leading to expression of proinflammatory cytokine [6] .
MKPs inactivate MAPK signaling [7] [8] [9] [10] [11] [12] . MKP dephosphorylates p38, ERK, and JNK MAPKs and negatively regulates MAPK signaling. MKPs are members of DUSPs, which remove phosphate groups from tyrosine, serine, and threonine residues of phosphorylated proteins [13] . MKP-1 (DUSP1) is an essential, endogenous, negative regulator of innate immune responses [7, 14 -16] . Knockdown of MKP-1 enhances the LPS-induced STAT1 phosphorylation and attenuates the nitroalkene-mediated inhibitory effects on iNOS expression and MCP-1 secretion [17] . MKP-1 null cells exhibited prolonged p38 activation and elevated IL-6 secretion compared with WT cells [18] . Inflammation in MKP-1 KO mice is accompanied by higher levels of TNF-␣ and IL-6 secretion, an increase in multiple organ failure, and higher mortality compared with WT mice [18 -21] .
MKP-1 is regulated by post-translational modifications. For example, phosphorylation of MKP-1 enhances MKP-1 stability [22] . Also, ROS inhibits JNK-dependent phosphatases, including MKP-1, by oxidizing catalytic cysteine residues to sulfenic acid [8, 23] .
We found previously that acetylation of MKP-1 plays a key role in regulating innate immunity [24] . We discovered that p300 and PCAF acetylate MKP-1, increasing its interaction with the MAPK member p38, decreasing phospho-p38 levels, and blunting innate immune signals. However, the HDAC that modifies MKP-1 is unknown. Here, we identify HDAC1, -2, and -3 as key enzymes that regulate MAPK signaling and innate immune signaling by deacetylating MKP-1.
MATERIALS AND METHODS

Cell culture and materials
The mouse macrophage cell line RAW264.7 (TIB-71; American Type Culture Collection, Manassas, VA, USA) was grown in RPMI, supplemented with 10% FBS and 1% penicillin/streptomycin. Primary macrophages were from mouse peritoneum without thioglycolate stimulation by peritoneal lavage with 5 ml PBS. LPS and MS-275 were purchased from Sigma-Aldrich (St. Louis, MO, USA). Macrophages were treated with MS-275 for 1 h before LPS treatment.
Antibodies to p38 (9218), phospho-p38 (4631), and pan acetyl-K (9441) were purchased from Cell Signaling Technology (Beverly, MA, USA). Antibodies to MKP-1 (sc-1199), NOS2 (sc-649), pan acetyl-K (sc-32268), MEK (sc-436), HDAC1 (sc-7872), HDAC2 (sc-7899, sc-81599), and HDAC3 (sc-11417, sc-17795) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibody to ␣-tubulin (T9026) was purchased from Sigma-Aldrich.
Mice
MKP-1 KO mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA) and bred on a C57BL/6J background. MKP-1 KO mice and their littermate WT controls were used as a source of peritoneal macrophages.
Immunoprecipitation and immunoblotting
Cells were lysed (20 mM PIPES, pH 7.0, 100 mM NaCl, 1 mM MgCl 2 , 0.1% Nonidet P-40, 20 mM Na 2 MoO 4 , 2 mM Na 3 VO 4 , 30 mM NaF, and protease inhibitors); immunoprecipitated for 1 h at 4°C with anti-HDAC1, -HDAC2, and -HDAC3, MKP-1, and pan acetyl-K antibodies; and then incubated with sepharose G beads overnight. Beads were washed with PBS and eluted with SDS-PAGE sample buffer. After SDS-PAGE, PVDF membranes were used for protein transfer and incubated with blocking solution with 5% dry milk for 1 h. Blots were incubated with primary antibodies for a minimum of 1 h and then HRP-conjugated second antibodies for 1 h. Afterward, washing blots were developed using a chemiluminescence kit (Pierce, Rockford, IL, USA).
In vitro deacetylation assays
The assay mixture contained 9 g biotinylated peptide MKP-1 RFSTIVR-RRAKGAMGLEHIVPNAELRGRLLA in the presence or absence of 1.2 g p300 HAT domain (14 -418; Upstate Biotechnology, Lake Placid, NY, USA), 0.25 Ci [ 14 C] acetyl-CoA, and 5ϫ HAT assay buffer. Before acetylation assay incubation, 5 l reaction mix from each reaction tube was saved and later analyzed on a separate gel as loading control. The acetylation reaction was carried out at 30°C for 1 h. Acetylated peptide was deacetylated with 1 g rHDAC1 (10009231; Cayman Chemical, Ann Arbor, MI, USA) at 30°C for 30 min. Then, acetylation of MKP-1 peptides was analyzed by Tricine gel and autoradiographed. The biotinylated MKP-1 peptide was also pulled down with streptavidin beads and counted in a radiation counter to asses MKP-1 acetylation.
RT-PCR
PCR was performed on total RNA harvested from RAW264.7 macrophages. PCR primers used were: HDAC1 forward, GAGACGGCATTGACGAC-GAATCCTAT, HDAC1 reverse, TGCGTTTATCAGAGGAGCAGATGGAG (555 bp); HDAC2 forward, TACAACAGATCGCGTGATGACCGT, HDAC2 reverse, AGCAACATTCCTACGACCTCCTTCAC (742 bp); HDAC3 forward, CAATGTGCCCTTACGAGATGGCATTG, HDAC3 reverse, CACCACAGAG-GTGACAAGGAACTCTT (680 bp); HDAC4 forward, AGAGGCTGAATGT-GAGCAAGATCCTC, HDAC4 reverse, ACGCAGGAGTGATACGGGTA-AGTTTC (852 bp); HDAC5 forward, GACTGCATTCAGGTCAAGGAT-GAGGA, HDAC5 reverse, CCATGGTGAATATCCCAGTCCACGAT (830 bp); HDAC6 forward, GAAGTGGAAGAAGCCGTGCTAGAAGA, HDAC6 reverse, CATACCGGTGCAGGGACACGTATAAT (679 bp); HDAC7 forward, CAA-GAAATCCCTGGAGAGACGCAAGA, HDAC7 reverse, ACTCCCTATGTTC-CAGGCCATCATTC (701 bp); HDAC8 forward, CCTGGGAATATTACGATT-GCGACGGA, HDAC8 reverse, AACCGCTTGCATCAACACACTGTC7 (34 bp); HDAC9 forward, AGGAGCACATCAAGGAACTTCTAGCC, HDAC9 reverse, ACACCTTGTCTGAGCATCTGTGTCTC (835 bp); HDAC10 forward, GGCCAGGGCATCCAGTATATCTTCAA, HDAC10 reverse, TCAA-GACTGACCCTTCTTGATGGAGC (781 bp); HDAC11 forward, AAGGAAGAAGGAAGCTGGGATTCTCC, HDAC11 reverse, GAAGGA-CACTATGAAGGCTGTGGGAA (647 bp); GAPDH forward, CGGAGT-CAACGGATTTGGTCGTAT, GAPDH reverse, AGCCTTCTCCATGGTG-GTGAAGAC.
The PCR cycle was: 95°C for 5 min, followed by 35 cycles of 94°C for 30 s to denature and 68°C for 30 s for elongation, according to the manufacturers' protocols (170-8890; Bio-Rad, Hercules, CA, USA; 639201; Clontech, Mountain View, CA, USA). iNOS primers were: iNOS forward, AATGGCAACATCAGGTCGGCCAT-CACT, iNOS reverse, GCTGTGTGTCACAGAAGCTCGAACTC; TNF-␣ primers were: TNF-␣ forward, GGTGTTCATCCATTCTCTACCCAGCC, TNF-␣ reverse, CTCAGGGAAGAGTCTGGAAAGGTCTG; IL-1␤ primers were: IL-1␤ forward, CTGTGTCTTCCTAAAGTATGGGCTGGAC, IL-1␤ reverse, CCACACGTTGACAGCTAGGTTCTGTTC; and IL-6 primers were: IL-6 forward, CCTCTGGTCTTCTGGAGTACCATAGCTA, IL-6 reverse, TCTGACCACAGTGAGGAATGTCCAC.
Amplification cycles of 35 were performed (1 min at 95°C, 1 min at 60°C, and 1.5 min at 72°C). A portion of PCR products was analyzed by 1% agarose gel electrophoresis and analyzed.
Silencing of HDACs in RAW264.7 macrophages
Three million RAW cells were electroporated with siRNAs against HDAC1 (M-042878-01-0005; Dharmacon, Lafayette, CO, USA), HDAC2 (M-046158-01-0005; Dharmacon), HDAC3 (M-043558-01-0005; Dharmacon), or a control siRNA (D-001210-02-05; Dharmacon) using a nucleofector (Amaxa, Lonza, Basel, Switzerland). Electroporated cells were incubated for 48 h and then stimulated with LPS.
Nitrite assay
Macrophages were cultured in phenol red-free medium with or without MS-275 and then with or without LPS. After 8 h, supernatant was collected. Nitrite levels were estimated by the Griess method.
Statistical analyses
Data are expressed as the mean Ϯ sd. Statistical comparisons were made by ANOVA, followed by Student's t-test. P Ͻ 0.05 was considered significant.
RESULTS
HDAC expression in macrophages
We first determined which HDAC isoforms are expressed in murine macrophages. In RAW 264.7 murine macrophages, RT-PCR for all HDAC isoforms (HDAC1-11) revealed an intense signal for HDAC1, -2, and -3 and negligible bands for HDAC4 -11 (Fig. 1A) . Mouse primary peritoneal macrophages expressed HDAC1, -2, and -3 and relatively low levels of HDAC9 (Fig. 1B) . RAW264.7 cells also express protein for HDAC1, -2, -3, -5, -7, -8, -9, and -10 but not HDAC4, -6, and -11 (Fig. 1C) .
HDAC1, -2, and -3 are members of class I HDACs, which reside inside the nucleus, as does MKP-1. Thus, we decided to study whether HDAC1, -2, or -3 deacetylates MKP-1 and regulates MAPK signaling. To prepare for our studies of HDAC and MKP-1, we first explored the effect of LPS and TSA upon expression of MKP-1 and HDAC1, -2, and -3. We pretreated RAW murine macrophages with or without the HDAC inhibitor TSA (100 ng/ml) for 1 h, then treated with or without LPS (100 ng/ml) for 1 h, and measured protein expression. LPS increases MKP-1 expression but does not affect levels of HDAC1, -2, and -3 ( Fig. 1D ).
HDAC1, -2, and -3 interact with MKP-1
As we had found previously that acetylation of MKP-1 is reversible [24] , we speculated that specific HDACs can associate with MKP-1. We first tested for an association of MKP-1 and HDAC isoforms in resting cells. To determine whether HDAC isoforms interact with MKP-1, we performed immunoprecipitation of resting cell lysates. We pulled down MKP-1 from cell lysates and immunoblotted precipitants with antibody to HDAC1, -2, and -3, and we also performed the reciprocal study-immunoprecipitating HDAC isoforms and immunoblotting for MKP-1. We could not detect an association of MKP-1 with HDAC1, -2, or -3 (data not shown). We inferred that MKP-1 was expressed at a low level under resting conditions and that MKP-1 was not associated with HDACs while the MAPK pathway was not activated.
We next explored whether MKP-1 interacts with HDAC isoforms in cells stimulated with LPS. We treated RAW cells with LPS (100 ng LPS for 3 h) and immunoprecipitated cell lysates as above (Fig. 2) . We found that HDAC1, -2, and -3 isoforms were associated with MKP-1 in cells treated with LPS (Fig. 2) . These data suggest that MKP-1 is the target of HDAC1, -2, and -3.
HDACs deacetylate MKP-1 in vitro and in vivo
To determine whether HDAC1 can deacetylate MKP-1, we performed in vitro and in vivo deacetylation experiments. We showed previously that MKP-1 can be acetylated in vitro and in vivo and that acetylation of MKP-1 increases the interaction between MKP-1 and p38, leading to an increase in MKP-1 phosphatase activity [24] . To explore HDAC deacetylation of MKP-1, we synthesized a biotinylated MKP-1 peptide extending from aa 47-76, which includes a lysine at residue 57, designated K57, as the substrate. We incubated K57 with an enzymatic active form of the p300 HAT domain and [
14 C] acetylCoA for 1 h and then added rHDAC1 for 0.5 h. As shown in our previous study [24] , p300 acetylated MKP-1 peptide, whereas rHDAC1 decreased acetylation of the K57 residue in the MKP-1 peptide, as detected by autoradiography and scintillography ( Fig. 3A and B) . The scintillation counts of in vitro acetylation, without p300, with p300, and with p300 and then HDAC1, are 3020 Ϯ 223, 4759 Ϯ 139, and 3030 Ϯ 142 (dpm), respectively (PϽ0.001).
To show that HDACs deacetylate MKP-1 in cells, we adopted genetic and pharmacologic approaches. In resting cells, MKP-1 acetylation was minimally detected, and simultaneous knockdown of HDAC1, -2, and -3 did not enhance MKP-1 acetylation (Fig. 3C) . MS-275 is a HDAC inhibitor specific for HDAC1, -2, and -3, but MS-275 is generally classified as a class I HDAC inhibitor [25, 26] . MS-275 treatment of RAW cells had no effect on MKP-1 acetylation in resting cells (Fig. 3C) . However, simultaneous knockdown of HDAC1, -2, and -3 increased MKP-1 acetylation in LPS-treated RAW macrophages (Fig. 3D) . Pretreatment of MS-275 also increased MKP-1 acetylation when the MAPK pathway was activated with LPS ( Fig. 3E) . Taken together, these data show that HDAC1, -2, and -3 deacetylate MKP-1.
Inhibition of individual HDAC isoforms does not affect phosphorylation of p38 MAPK
If HDAC isoforms deacetylate MKP-1, inhibition of HDAC isoforms should inhibit MAPK signaling. To test this hypothesis, we first used siRNA to knock down class I HDAC isoforms (Fig. 4A) . However, silencing of HDAC1 alone not only decreased HDAC1 expression but also gave rise to a compensatory increase in HDAC2 (Fig. 4B) . Similarly, silencing of HDAC2 led to a compensatory increase in HDAC1 (Fig. 4C) , and silencing of HDAC3 led to a compensatory increase in HDAC1 (Fig. 4D) . Furthermore, silencing of individual HDAC isoforms did not affect p38 phosphorylation (Fig. 4B-D) . Silencing of HDAC1 and -2 decreased expression of both isoforms but led to an increase in HDAC3 expression and also failed to affect p38 phosphorylation (Fig. 4E) . Consistently, individual silencing of HDAC1, -2, or -3 did not significantly affect MKP-1 acetylation in RAW macrophages., Our data suggest that cells compensate for decreased HDAC isoform expression by increasing expression of other HDAC isoforms and that any of these three HDAC isoforms can deacetylate MKP-1. However, simultaneous silencing of HDAC1, -2, and -3 increased MKP-1 acetylation in cells activated with LPS (Figs. 3D and 4F ).
Simultaneous inhibition of HDAC1, -2, and -3 decreased phosphorylation of p38 MAPK
Next, we decided to simultaneously knock down all of HDAC1, -2, and -3 and explore the effect in the phosphorylation of p38. We found that silencing of all three HDAC isoforms, HDAC1, -2, and -3, effectively decreased the levels of activated p38 (Fig. 5A) . These data suggest that HDAC1, -2, and -3 all contribute to the deacetylation of MKP-1 and p38 dephosphorylation by MKP-1.
We next used a pharmacological approach to test the ability of HDACs to deacetylate MKP-1 using MS-275. We pretreated RAW macrophages with control (DMSO) or MS-275 for 1 h and then stimulated them with LPS for 0.5 h. MS-275 dosedependently decreased p38 phosphorylation (Fig. 5B) .
To show that HDACs regulate p38 phosphorylation through MKP-1 deacetylation, we pretreated primary peritoneal macro- phages from WT and MKP-1 KO mice with MS-275 before LPS stimulation. Whereas MS-275 pretreatment decreased LPSinduced p38 phosphorylation in WT primary peritoneal macrophages ( Fig. 5C ; adjusted densitometry value 9.7 vs. 5.9; PϽ0.05), MS-275 pretreatment had no effect upon p38 phosphorylation in MKP-1 null primary macrophages ( Fig. 5D ; adjusted densitometry value 2.7 vs. 2.7; PϾ0.05).
Taken together, these data suggest that HDACs regulate p38 MAPK signaling, in part, by deacetylating MKP-1. Furthermore, HDAC1, -2, and -3 work together in regulating MKP-1.
HDAC1, -2, and -3 regulate LPS-induced proinflammatory cytokine production
We next explored the effect of HDAC1, -2, and -3 inhibitions upon expression of iNOS, whose expression depends on the MAPK pathway. Genetic silencing of HDAC1, -2, and -3 decreased LPS induction of iNOS in RAW cells (Fig. 6A) . Similarly, pharmacologic inhibition of HDACs using MS-275 decreased LPS-induced iNOS expression in RAW cells and primary peritoneal macrophages (Fig. 6B and C) . Consequently, LPS-induced nitrite production in RAW cells was decreased by MS-275 pretreatment (Fig. 6D) . To show the effect of HDAC1, -2, and -3 inhibitions on other proinflammatory cytokine expressions, we also measured the expression of TNF-␣, IL-1␤, and IL-6. Simultaneous knockdown of HDAC1, -2, and -3 significantly reduced induction of TNF-␣ (adjusted densitometry value 8.8 vs. 3.0; PϽ0.05), iNOS (adjusted densitometry value 11.0 vs. 3.5; PϽ0.05), and IL-1␤ (adjusted densitometry value 10.4 vs. 5.9; PϽ0.05) by LPS in RAW cells, but its inhibitory effect on IL-6 induction is not significant (adjusted densitometry value 6.5 vs. 6.2; Fig. 6E ).
DISCUSSION
HDAC regulation of MAPK signaling and inflammation
The major finding of our study is that HDAC isoforms HDAC1, -2, and -3 deacetylate MKP-1. Deacetylation of MKP-1 leads to increased MAPK signaling and increased expression of inflammatory mediators. Our previous identification of p300 and PCAF acetylation of MKP-1 and our current observation of HDAC deacetylation of MKP-1 establish that acetylation of MKP-1 is dynamic and reversible.
HDAC isoforms
HATs and HDACs promote and repress gene transcription by adding and removing acetyl groups from the lysine residues of histone proteins. HATs and HDACs also acetylate and deacetylate nonhistone proteins, such as p53, NF-B, Stat3, and heat shock protein 90, and modulate their activity [27] [28] [29] [30] [31] [32] . HDAC isoforms are categorized into four groups according to their homology to the yeast HDACs [33, 34] . Class I HDAC includes HDAC1, -2, -3, and -8; class II HDAC includes HDAC4, -5, -6, -7, -9, and -10; class III HDAC, also known as SIRTs, includes SIRT1-7. HDAC11 is grouped alone into class IV. Class I, II, and IV HDACs are inhibited by TSA, sodium butyrate, and SAHA. HDAC inhibitors have been reported to reduce inflammatory responses and cytokine production. For example, butyrate inhibits NO production from macrophages [35] . Similarly, TSA decreases proinflammatory cytokine production, such as TNF-␣, IL-6, IL-12, and NO [36, 37] . In mice, a single oral administration of SAHA dose-dependently decreased LPS-induced TNF-␣ IL-1␤, IL-6, and IFN-␥ levels in peripheral blood [38] . HDAC inhibitors decrease inflammation in mouse models of glomerulonephritis, sepsis, asthma, and graft-versus-host disease [24, 36, 38 -42] .
Novel pathways for HDAC regulation of inflammation
Our data suggest a new pathway by which HDACs regulate immune responses. Others have shown that HDACs deacetylate histones and globally influence expression of inflammatory genes. For example, HDACs decrease transcription of specific cytokine genes by deacetylating associated histones [43] [44] [45] . In addition, others have found that HDACs directly deacetylate nonhistone proteins, which regulate inflammatory gene transcription, such as Stat3, glucocorticoid receptor, NF-B, and IB [27, 28, 32, 35, 46, 47] . For example, HDAC deacetylation of NF-B regulates its ability to interact with IB and to transactivate promoters bearing B-binding sites [47] . In addition, HDACs can deacetylate Stat3, decreasing Stat3-driven transcription [32] . Our study identifies MKP-1 as a novel target of HDACs and shows that HDACs can regulate stress signaling through the MAPK cascade.
HDAC1, -2, and -3 compensated expression
We found that genetic silencing of one HDAC isoform led to an increase in expression of another HDAC isoform. Knockdown of HDAC1 led to an increase in HDAC2 levels; knockdown of HDAC2 led to an increase of HDAC1. These results confirm the work of others. For example, HDAC2 expression is increased in HDAC1-deficient cells, such as mouse embryonic stem cells, fibroblasts, T cells, and various human cancer cells, [48 -51] . We also found that knockdown of HDAC1 and -2 together led to an increase in HDAC3 expression and furthermore, that silencing of HDAC3 increases HDAC1 expression. These data suggest that HDAC isoforms can compensate for one another for the deacetylation of MKP-1.
What is the mechanism of compensation among HDAC isoforms? One possible mechanism is that HDAC1 and -2 interact with and deacetylate each other. HDAC1 and -2 are components of large deacetylase complexes, such as the mSin3A, NuRD/ NRD/Mi2, and CoREST complexes [52] [53] [54] [55] . Furthermore, HDAC1 is acetylated, and acetylation of HDAC1 inactivates its deacetylase activity [56] . Thus, it may be possible that normally, HDAC1 and -2 deacetylate each other and that the absence of one isoform may permit increased acetylation of its counterpart, decreasing its deacetylase activity and leading to its overexpression. Another possible mechanism for compensation is that one HDAC isoform negatively regulates the gene transcription of the other HDAC isoform. For instance, histones associated with the HDAC2 promoter are hyperacetylated in HDAC1-deficient cells [57] . Collectively, our data support the idea that HDACs may regulate their own gene transcription and acetylation. Which HDAC isoforms regulate the MAPK pathway in cells? Although RAW cells express several HDAC isoforms, our data suggest that HDAC1, -2, and -3 are involved in inflammatory signaling, as simultaneous knockdown of all three HDAC isoforms regulates phosphorylation of p38 (Fig. 5A) . Similarly, pharmacological inhibition of HDAC1, -2, and -3, using the class I HDAC inhibitor MS-275, decreased phosphorylation of p38 (Fig. 5B) . Thus, our studies do not specify an individual HDAC but rather, a set of HDAC isoforms (HDAC1, -2, and -3) as deacetylating enzymes for MKP-1. Furthermore, our study suggests that HDACs as well as MKP-1 may be therapeutic targets for inflammatory diseases.
MKP-1 as a regulatory switch for innate-immune signaling
Dynamic regulation of acetyltransferases and deacetylases plays an important role in controlling cellular responses to stress [58] . Our data suggest that acetylation and deacetylation of MKP-1 act as a switch to control innate-immune responses. We showed previously that the acetyltransferases p300 or PCAF can attach an acetyl group to the K57 residue of MKP-1, and our current data identify HDAC1, -2, and -3 as deacetylases that can remove acetyl from MKP-1. Thus, the acetylation status of MKP-1 is controlled, in part, by regulation of these enzymes.
Possible mechanisms for regulation of acetyltransferases and deacetylases include subcellular localization, interaction partners, post-translational modifications, proteolytic processing, and availability of substrates. Many regulators of p300 and PCAF have been identified. Acetyltransferase activity of p300 and PCAF can be inhibited by post-translational modifications; for example, p300 can be autoacetylated to increase its activity; Sirt1 can deacetylate PCAF, decreasing PCAF acetyltransferase activity [59] ; and p300 can be sumoylated, which suppresses its activity [60] . p300 can be phosphorylated and stimulated by cyclin E CDK2, CaM kinase IV, or 90-kDa ribosomal S6 kinase [61] [62] [63] . Acetyltransferase activity of p300 and PCAF can also be inhibited by proteins, such as Twist, which directly binds the HAT domain of p300 and PCAF [64] . Translation of PCAF can be regulated by many factors, including microRNA [65] .
In addition, many regulators of HDAC have been discovered. For example, p300 acetylates and inactivates HDAC1. Inositol phosphates regulate HDAC3 [66] . Sequestration of some HDAC in the cytoplasm regulates HDAC function [67] . HDAC3 can be phosphorylated by protein kinase casein kinase 2 and dephosphorylated by protein serine/threonine phosphatase 4 complex [68] Thus, there are many factors that could control whether or not MKP-1 is acetylated.
Use of HDAC inhibitors in inflammatory diseases
Several studies have reported that HDAC inhibitors can suppress inflammation in vivo. For example, treatment with the HDAC inhibitor TSA significantly improves glomerulonephritis and re- . (E) Genetic silencing of HDAC. RAW macrophages were transfected with siRNA against HDAC1, -2, and -3 or control as above and stimulated with LPS 100 ng/ml for 6 h, and RT-PCR was performed to measure the induction of TNF-␣, iNOS, IL-1␤, and IL-6. GAPDH was used as control. *P Ͻ 0.05, while lanes 3 and 4 compared. duces proteinuria in MRL-lpr/lpr mice [36] . Also, the HDAC inhibitor SAHA decreases proinflammatory cytokine levels, morbidity, and mortality in graft-versus-host disease in mice [41] . In a mouse model of asthma, inflammatory infiltrates and mucus-plugging are diminished by TSA [39] . HDAC inhibitors, such as TSA or KBH-A42, decrease the production of proinflammatory cytokine in a murine model of endotoxic shock [24, 38, 40] . However, the exact mechanisms by which HDAC inhibitors regulate inflammatory diseases are not well-defined yet. Our studies suggest a novel pathway through which HDAC inhibitors suppress inflammation in vivo, namely, by affecting the balance between acetylation and deacetylation of MKP-1.
In summary, the major finding of our study is that HDACs regulate TLR signaling by deacetylating MKP-1. Macrophages express HDAC isoforms, and HDAC1, -2, and -3 interact with MKP-1. HDAC1, -2, and -3 jointly modulate phosphorylation of p38 and iNOS expression by deacetylating MKP-1. HDAC1, -2, and -3 may be positive regulators in innate-immune signaling pathway and potential therapeutic targets for inflammatory diseases (Fig. 7) . AUTHORSHIP Y.J. participated in experimental design, performing experiments, and writing the manuscript. R.D. performed some immunoprecipitation and RT-PCR experiments. X.Z. performed some Western blotting and acetylation assay. S.Y. performed some cell culture and Western blotting. J.W. participated in experimental design. H.C. participated in editing the manuscript. W.C. participated in experimental design, acetylation assay, and writing the manuscript. C.J.L. participated in experimental design and editing the manuscript.
